WO2011069527A1 - Schéma de traitement pour idd et autres maladies auto-immunes - Google Patents

Schéma de traitement pour idd et autres maladies auto-immunes Download PDF

Info

Publication number
WO2011069527A1
WO2011069527A1 PCT/EP2009/008801 EP2009008801W WO2011069527A1 WO 2011069527 A1 WO2011069527 A1 WO 2011069527A1 EP 2009008801 W EP2009008801 W EP 2009008801W WO 2011069527 A1 WO2011069527 A1 WO 2011069527A1
Authority
WO
WIPO (PCT)
Prior art keywords
bcg
cells
treatment
combination
active agents
Prior art date
Application number
PCT/EP2009/008801
Other languages
English (en)
Inventor
Ulrich Freiherr Von Arnim
Original Assignee
Ulrich Freiherr Von Arnim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulrich Freiherr Von Arnim filed Critical Ulrich Freiherr Von Arnim
Priority to PCT/EP2009/008801 priority Critical patent/WO2011069527A1/fr
Publication of WO2011069527A1 publication Critical patent/WO2011069527A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

La présente invention concerne une combinaison d'agents actifs comprenant un immunopotentialisateur et de l'héparine. La présente invention concerne en outre l'utilisation d'une combinaison d'agents actifs pour le traitement du diabète de type I.
PCT/EP2009/008801 2009-12-09 2009-12-09 Schéma de traitement pour idd et autres maladies auto-immunes WO2011069527A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/008801 WO2011069527A1 (fr) 2009-12-09 2009-12-09 Schéma de traitement pour idd et autres maladies auto-immunes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2009/008801 WO2011069527A1 (fr) 2009-12-09 2009-12-09 Schéma de traitement pour idd et autres maladies auto-immunes

Publications (1)

Publication Number Publication Date
WO2011069527A1 true WO2011069527A1 (fr) 2011-06-16

Family

ID=41820272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/008801 WO2011069527A1 (fr) 2009-12-09 2009-12-09 Schéma de traitement pour idd et autres maladies auto-immunes

Country Status (1)

Country Link
WO (1) WO2011069527A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158288A1 (en) * 2002-06-27 2005-07-21 Faustman Denise L. Methods of organ regeneration
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
WO2006078782A2 (fr) * 2005-01-18 2006-07-27 The General Hospital Corporation Compositions contenant des cellules d'agm et procedes pour les utiliser
US20090220518A1 (en) * 2005-06-07 2009-09-03 Regents Of The University Of Colorado Methods and compositions for treatment of graft rejection and promotion of graft survival
CN101584704A (zh) * 2008-05-23 2009-11-25 鲁南制药集团股份有限公司 肝素、低分子肝素可药用盐或其衍生物的医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158288A1 (en) * 2002-06-27 2005-07-21 Faustman Denise L. Methods of organ regeneration
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
WO2006078782A2 (fr) * 2005-01-18 2006-07-27 The General Hospital Corporation Compositions contenant des cellules d'agm et procedes pour les utiliser
US20090220518A1 (en) * 2005-06-07 2009-09-03 Regents Of The University Of Colorado Methods and compositions for treatment of graft rejection and promotion of graft survival
CN101584704A (zh) * 2008-05-23 2009-11-25 鲁南制药集团股份有限公司 肝素、低分子肝素可药用盐或其衍生物的医药用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARTICO M ET AL: "Diabetic rats treated by low molecular weight heparin OP 2123/parnaparin - Morphological changes in the kidney and heart", JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol. 18, no. 2, March 2004 (2004-03-01), pages 119 - 125, XP002575277, ISSN: 1056-8727 *
DATABASE WPI Week 201002, Derwent World Patents Index; AN 2009-S18504, XP002575278 *
HAN ZHONG CHAO ET AL: "Heparin acts synergistically with thrombopoietin and interleukin-6 in stimulating megakaryocytopoiesis", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 24, no. 9, 1 January 1996 (1996-01-01), pages 1068, XP008120680, ISSN: 0301-472X *
ISTVAN JOKAY ET AL: "Effect of heparin on the priming with a protein antigen in mice", ZEITSCHRIFT FUER IMMUNITAETSFORSCHUNG, STUTTGART, DE, vol. 152, no. 4, 1 January 1976 (1976-01-01), pages 343 - 348, XP008120679, ISSN: 0340-904X *
MATOUS-MALBOHAN I ET AL: "Influence of heparin and protamine on enlargement of the draining lymph node during induction of EAE", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 12, no. 3, 1 June 1974 (1974-06-01), pages 345 - 349, XP024000760, ISSN: 0008-8749, [retrieved on 19740601] *
SHEHADEH NAIM ET AL: "Effect of adjuvant therapy on development of diabetes in mouse and man", LANCET (NORTH AMERICAN EDITION), vol. 343, no. 8899, 1994, pages 706 - 707, XP002575276, ISSN: 0099-5355 *

Similar Documents

Publication Publication Date Title
Kim et al. T-helper types 1, 2, and 3 cytokine interactions in symptomatic manic patients
Secor Jr et al. Bromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model of allergic airway disease
Haslett et al. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
Ekhlasi et al. Effects of symbiotic and vitamin E supplementation on blood pressure, nitric oxide and inflammatory factors in non-alcoholic fatty liver disease
CN100528222C (zh) 共聚物-1在制备治疗多发性硬化症的口服固体药物中的用途
Zhang et al. Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response
RU2702632C2 (ru) Новые комбинации для антигенной терапии
Hagenlocher et al. Cinnamon extract reduces symptoms, inflammatory mediators and mast cell markers in murine IL-10−/− colitis
Cvjetićanin et al. Dried leaf extract of Olea europaea ameliorates islet-directed autoimmunity in mice
AU2010260585B2 (en) Compositions and methods for treatment of Multiple Sclerosis
JP2016188214A (ja) グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
Jo et al. Antiallergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA)
Schloot et al. DiaPep277® and immune intervention for treatment of type 1 diabetes
Bocci et al. The clinical application of ozonetherapy
Zyla et al. Dimethyl fumarate mitigates optic neuritis
Blaylock et al. The central role of excitotoxicity in autism spectrum disorders
Dobrosavljevic et al. Toxic epidermal necrolysis following morbilli‐parotitis‐rubella vaccination
Jiang et al. MOG35–55 iv suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways
WO2011069527A1 (fr) Schéma de traitement pour idd et autres maladies auto-immunes
KR101324647B1 (ko) 다발성신경경화증의 치료 또는 예방용 조성물 및 이의 스크리닝 방법
EP1038529A2 (fr) Agent permettant d'augmenter la production de chimiokine
Vassar et al. Evaluation of prostaglandin E1 for prevention of respiratory failure in high risk trauma patients: a prospective clinical trial and correlation with plasma suppressive factors for neutrophil activation
Cruess et al. Biobehavioral Bases of Disease Processes.
Stowers Treatment of subclinical diabetes.
EP4046639A1 (fr) Prévention de la fuite vasculaire pulmonaire dans la covid-19

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09796621

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09796621

Country of ref document: EP

Kind code of ref document: A1